journal
https://read.qxmd.com/read/38630999/fair-allocation-of-glp-1-and-dual-glp-1-gip-receptor-agonists
#1
JOURNAL ARTICLE
Ezekiel J Emanuel, Johan L Dellgren, Matthew S McCoy, Govind Persad
No abstract text is available yet for this article.
April 17, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38624029/silver-resident
#2
JOURNAL ARTICLE
Farrin A Manian
No abstract text is available yet for this article.
April 13, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38624028/expanding-applications-of-clinical-genetic-testing-ethical-challenges
#3
JOURNAL ARTICLE
Stephanie M Fullerton, Kyle B Brothers
No abstract text is available yet for this article.
April 13, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38624022/hemotympanum-with-a-basilar-skull-fracture
#4
JOURNAL ARTICLE
Carlos Carazo Casas, Marimar Medina Gonzalez
No abstract text is available yet for this article.
April 13, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38624016/advocating-for-a-healthy-response-to-climate-change-cop28-and-the-health-community
#5
JOURNAL ARTICLE
Jeni Miller, Courtney Howard, Lujain Alqodmani
No abstract text is available yet for this article.
April 13, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38624001/twenty-five-years-after-columbine-firearms-and-public-health-in-the-united-states
#6
JOURNAL ARTICLE
David Hemenway
No abstract text is available yet for this article.
April 13, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38598820/corporate-medicine-2-0-special-purpose-acquisition-companies-in-the-united-states
#7
JOURNAL ARTICLE
Nishant Uppal, Zirui Song
No abstract text is available yet for this article.
April 10, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38598818/integrating-public-health-and-health-care-protecting-health-as-a-team-sport
#8
JOURNAL ARTICLE
Charlene A Wong, Debra Houry, Mandy K Cohen
No abstract text is available yet for this article.
April 10, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38588025/transcatheter-or-surgical-treatment-of-aortic-valve-stenosis
#9
JOURNAL ARTICLE
Stefan Blankenberg, Moritz Seiffert, Reinhard Vonthein, Helmut Baumgartner, Sabine Bleiziffer, Michael A Borger, Yeong-Hoon Choi, Peter Clemmensen, Jochen Cremer, Martin Czerny, Nina Diercks, Ingo Eitel, Stephan Ensminger, Derk Frank, Norbert Frey, Andreas Hagendorff, Christian Hagl, Christian Hamm, Utz Kappert, Matthias Karck, Won-Keun Kim, Inke R König, Markus Krane, Ulf Landmesser, Axel Linke, Lars S Maier, Steffen Massberg, Franz-Josef Neumann, Hermann Reichenspurner, Tanja K Rudolph, Christof Schmid, Holger Thiele, Raphael Twerenbold, Thomas Walther, Dirk Westermann, Erion Xhepa, Andreas Ziegler, Volkmar Falk
BACKGROUND: Among low-risk patients with severe, symptomatic aortic stenosis who are eligible for both transcatheter aortic-valve implantation (TAVI) and surgical aortic-valve replacement (SAVR), data are lacking on the appropriate treatment strategy in routine clinical practice. METHODS: In this randomized noninferiority trial conducted at 38 sites in Germany, we assigned patients with severe aortic stenosis who were at low or intermediate surgical risk to undergo either TAVI or SAVR...
April 8, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38588008/another-early-win-for-tavi-in-low-risk-patients
#10
EDITORIAL
Pinak B Shah
No abstract text is available yet for this article.
April 8, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38588006/role-of-physiology-in-the-management-of-nonculprit-lesions-in-acute-coronary-syndrome
#11
EDITORIAL
Vijay Kunadian
No abstract text is available yet for this article.
April 8, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38587995/ffr-guided-complete-or-culprit-only-pci-in-patients-with-myocardial-infarction
#12
JOURNAL ARTICLE
Felix Böhm, Brynjölfur Mogensen, Thomas Engstrøm, Goran Stankovic, Ilija Srdanovic, Jacob Lønborg, Sammy Zwackman, Mehmet Hamid, Thomas Kellerth, Jörg Lauermann, Olli A Kajander, Jonas Andersson, Rikard Linder, Oskar Angerås, Henrik Renlund, Andrejs Ērglis, Madhav Menon, Carl Schultz, Mika Laine, Claes Held, Andreas Rück, Ollie Östlund, Stefan James
BACKGROUND: The benefit of fractional flow reserve (FFR)-guided complete revascularization in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease remains unclear. METHODS: In this multinational, registry-based, randomized trial, we assigned patients with STEMI or very-high-risk non-STEMI (NSTEMI) and multivessel disease who were undergoing primary percutaneous coronary intervention (PCI) of the culprit lesion to receive either FFR-guided complete revascularization of nonculprit lesions or no further revascularization...
April 8, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38587261/self-expanding-or-balloon-expandable-tavr-in-patients-with-a-small-aortic-annulus
#13
JOURNAL ARTICLE
Howard C Herrmann, Roxana Mehran, Daniel J Blackman, Stephen Bailey, Helge Möllmann, Mohamed Abdel-Wahab, Walid Ben Ali, Paul D Mahoney, Hendrik Ruge, David A Wood, Sabine Bleiziffer, Basel Ramlawi, Hemal Gada, Anna Sonia Petronio, Charles D Resor, William Merhi, Bruno Garcia Del Blanco, Guilherme F Attizzani, Wayne B Batchelor, Linda D Gillam, Mayra Guerrero, Toby Rogers, Joshua D Rovin, Molly Szerlip, Brian Whisenant, G Michael Deeb, Kendra J Grubb, Ratnasari Padang, Myra T Fan, Andrew D Althouse, Didier Tchétché
BACKGROUND: Patients with severe aortic stenosis and a small aortic annulus are at risk for impaired valvular hemodynamic performance and associated adverse cardiovascular clinical outcomes after transcatheter aortic-valve replacement (TAVR). METHODS: We randomly assigned patients with symptomatic severe aortic stenosis and an aortic-valve annulus area of 430 mm2 or less in a 1:1 ratio to undergo TAVR with either a self-expanding supraannular valve or a balloon-expandable valve...
April 7, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38587255/routine-beta-blockers-in-secondary-prevention-on-injured-reserve
#14
EDITORIAL
P Gabriel Steg
No abstract text is available yet for this article.
April 7, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38587251/mechanical-circulatory-support-in-cardiogenic-shock-persistence-and-progress
#15
EDITORIAL
Sunil V Rao
No abstract text is available yet for this article.
April 7, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38587249/olezarsen-for-hypertriglyceridemia-in-patients-at-high-cardiovascular-risk
#16
JOURNAL ARTICLE
Brian A Bergmark, Nicholas A Marston, Thomas A Prohaska, Veronica J Alexander, André Zimerman, Filipe A Moura, Sabina A Murphy, Erica L Goodrich, Shuanglu Zhang, Daniel Gaudet, Ewa Karwatowska-Prokopczuk, Sotirios Tsimikas, Robert P Giugliano, Marc S Sabatine
BACKGROUND: Reducing the levels of triglycerides and triglyceride-rich lipoproteins remains an unmet clinical need. Olezarsen is an antisense oligonucleotide targeting messenger RNA for apolipoprotein C-III (APOC3), a genetically validated target for triglyceride lowering. METHODS: In this phase 2b, randomized, controlled trial, we assigned adults either with moderate hypertriglyceridemia (triglyceride level, 150 to 499 mg per deciliter) and elevated cardiovascular risk or with severe hypertriglyceridemia (triglyceride level, ≥500 mg per deciliter) in a 1:1 ratio to either a 50-mg or 80-mg cohort...
April 7, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38587248/shooting-the-messenger-to-treat-hypertriglyceridemia
#17
EDITORIAL
Gerald F Watts
No abstract text is available yet for this article.
April 7, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38587247/olezarsen-acute-pancreatitis-and-familial-chylomicronemia-syndrome
#18
JOURNAL ARTICLE
Erik S G Stroes, Veronica J Alexander, Ewa Karwatowska-Prokopczuk, Robert A Hegele, Marcello Arca, Christie M Ballantyne, Handrean Soran, Thomas A Prohaska, Shuting Xia, Henry N Ginsberg, Joseph L Witztum, Sotirios Tsimikas
BACKGROUND: Familial chylomicronemia syndrome is a genetic disorder associated with severe hypertriglyceridemia and severe acute pancreatitis. Olezarsen reduces the plasma triglyceride level by reducing hepatic synthesis of apolipoprotein C-III. METHODS: In a phase 3, double-blind, placebo-controlled trial, we randomly assigned patients with genetically identified familial chylomicronemia syndrome to receive olezarsen at a dose of 80 mg or 50 mg or placebo subcutaneously every 4 weeks for 53 weeks...
April 7, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38587241/beta-blockers-after-myocardial-infarction-and-preserved-ejection-fraction
#19
JOURNAL ARTICLE
Troels Yndigegn, Bertil Lindahl, Katarina Mars, Joakim Alfredsson, Jocelyne Benatar, Lisa Brandin, David Erlinge, Ola Hallen, Claes Held, Patrik Hjalmarsson, Pelle Johansson, Patric Karlström, Thomas Kellerth, Toomas Marandi, Annica Ravn-Fischer, Johan Sundström, Ollie Östlund, Robin Hofmann, Tomas Jernberg
BACKGROUND: Most trials that have shown a benefit of beta-blocker treatment after myocardial infarction included patients with large myocardial infarctions and were conducted in an era before modern biomarker-based diagnosis of myocardial infarction and treatment with percutaneous coronary intervention, antithrombotic agents, high-intensity statins, and renin-angiotensin-aldosterone system antagonists. METHODS: In a parallel-group, open-label trial performed at 45 centers in Sweden, Estonia, and New Zealand, we randomly assigned patients with an acute myocardial infarction who had undergone coronary angiography and had a left ventricular ejection fraction of at least 50% to receive either long-term treatment with a beta-blocker (metoprolol or bisoprolol) or no beta-blocker treatment...
April 7, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38587239/microaxial-flow-pump-or-standard-care-in-infarct-related-cardiogenic-shock
#20
JOURNAL ARTICLE
Jacob E Møller, Thomas Engstrøm, Lisette O Jensen, Hans Eiskjær, Norman Mangner, Amin Polzin, P Christian Schulze, Carsten Skurk, Peter Nordbeck, Peter Clemmensen, Vasileios Panoulas, Sebastian Zimmer, Andreas Schäfer, Nikos Werner, Martin Frydland, Lene Holmvang, Jesper Kjærgaard, Rikke Sørensen, Jacob Lønborg, Matias G Lindholm, Nanna L J Udesen, Anders Junker, Henrik Schmidt, Christian J Terkelsen, Steffen Christensen, Evald H Christiansen, Axel Linke, Felix J Woitek, Ralf Westenfeld, Sven Möbius-Winkler, Kristian Wachtell, Hanne B Ravn, Jens F Lassen, Søren Boesgaard, Oke Gerke, Christian Hassager
BACKGROUND: The effects of temporary mechanical circulatory support with a microaxial flow pump on mortality among patients with ST-segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock remains unclear. METHODS: In an international, multicenter, randomized trial, we assigned patients with STEMI and cardiogenic shock to receive a microaxial flow pump (Impella CP) plus standard care or standard care alone. The primary end point was death from any cause at 180 days...
April 7, 2024: New England Journal of Medicine
journal
journal
20199
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.